Latest news with #Avacta
Malaysian Reserve
07-08-2025
- Business
- Malaysian Reserve
FAP Inhibitors Market Analysis Across the 7MM: Key Insights and Outlook Through 2040
According to DelveInsight's analysis, the growth of the FAP inhibitor market is expected to be primarily driven by the anticipated launch of several emerging therapies such as [18F] FAPI-74, [68Ga] FAPI-46, AZD2389, BXCL701, AVA6000, and others targeting a range of indications. LAS VEGAS, Aug 7, 2025 /PRNewswire/ — DelveInsight's FAP Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging FAP inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into 7MM. Key Takeaways from the FAP Inhibitors Market Report As per DelveInsight's analysis, the total market size of FAP inhibitors in the 7MM is expected to surge significantly by 2040. The report provides the total potential number of patients in the indications, such as NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others. Leading FAP inhibitor companies, such as SOFIE, BioXcel, OnkosXcel, AstraZeneca, Avacta, and others, are developing novel FAP inhibitors that can be available in the FAP inhibitors market in the coming years. Some of the key FAP inhibitors in the pipeline include [18F]FAPI-74, [68Ga]FAPI-46, BXCL701, AZD 2389, AVA6000, and others. In March 2025, Avacta announced promising early efficacy and safety data for AVA6000 in the Phase Ia Dose Escalation and ongoing enrollment in the Phase Ib Expansion Cohorts. In February 2024, BioXcel Therapeutics received US FDA Fast Track Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. Discover which indication is expected to grab the major FAP inhibitors market share @ FAP Inhibitors Market Report FAP Inhibitors Market Dynamics The FAP inhibitors market is gaining momentum as the understanding of FAP's role in various pathological conditions, particularly cancer and fibrosis, continues to evolve. FAP is highly expressed in cancer-associated fibroblasts (CAFs) within the tumor microenvironment and in fibrotic tissues, but is largely absent in normal adult tissues. This selective expression profile has made FAP an attractive target for therapeutic intervention, as it allows for more precise targeting of tumor stroma or fibrotic lesions with reduced off-target effects. As a result, the FAP inhibitor landscape is witnessing increased research and development activities from both pharmaceutical companies and academic institutions. Market growth is being fueled by multiple clinical programs evaluating FAP inhibitors in oncology, particularly in solid tumors such as pancreatic, breast, lung, and colorectal cancers. These inhibitors are being studied both as monotherapies and in combination with other agents like immune checkpoint inhibitors and chemotherapeutics. Several radiolabeled FAP inhibitors are also advancing in the diagnostics space, especially in PET imaging, offering real-time assessment of tumor burden and stromal activity. The dual diagnostic and therapeutic potential (theranostics) of FAP-targeting agents enhances their market appeal, with companies seeking to develop companion diagnostics and targeted radioligand therapies. Despite the promising potential, challenges persist in optimizing the pharmacokinetics, safety profiles, and therapeutic windows of FAP inhibitors. Many compounds in development are still in early- to mid-stage clinical trials, and efficacy data remain limited. Additionally, while FAP overexpression is common across various tumors, patient stratification and biomarker-driven approaches will be critical for successful commercialization. Addressing these challenges through improved drug design and clinical validation will be key to unlocking the full potential of this drug class. From a competitive standpoint, the market is moderately fragmented, with a mix of biotech startups and large pharmaceutical companies pursuing differentiated approaches. Some developers are focusing on small molecules, while others are leveraging antibody-drug conjugates (ADCs), bispecific antibodies, or FAP-targeted radiopharmaceuticals. Strategic collaborations, licensing deals, and academic partnerships are becoming common, as companies seek to access novel platforms and reduce development risk. This dynamic landscape suggests significant potential for innovation, particularly in niche indications where conventional therapies have limited efficacy. In the coming years, the FAP inhibitors market is expected to benefit from growing interest in tumor microenvironment modulation, expanding applications in fibrotic diseases, and increased investment in precision medicine. Regulatory pathways for novel cancer and fibrosis therapeutics continue to evolve, potentially accelerating time-to-market for promising FAP-targeted agents. With no approved therapies currently available, the first entrants into the market stand to capture substantial value, especially if they demonstrate meaningful clinical benefit in underserved patient populations. FAP Inhibitors Treatment Market FAPI belongs to a novel class of tracers with emerging roles in cancer diagnosis and therapy. Clinical trials are actively investigating the safety and efficacy of FAP inhibitors for both oncologic and fibrotic conditions, with several candidates advancing into mid-stage trials. Currently, no FAP inhibitors have received regulatory approval. While challenges remain, such as enhancing drug delivery and reducing toxicity, FAP-targeted therapies represent a promising step forward in precision treatment for cancer and fibrotic diseases. Continued research and clinical validation could position FAP inhibitors as an innovative option for patients with these complex conditions. FAP has gained recognition as a specific biomarker for carcinoma-associated fibroblasts (CAFs) and activated fibroblasts found in tissues undergoing extracellular matrix (ECM) remodeling due to persistent inflammation, fibrosis, or tissue repair. FAPI agents have been studied extensively across multiple tumor types, in both diagnostic imaging and therapeutic applications. The tumor microenvironment (TME), predominantly consisting of ECM components like blood vessels, cytokines, growth factors, and fibroblasts, plays a central role in cancer development. Fibroblasts contribute to collagen synthesis and modulate local inflammatory and homeostatic processes. A specialized subgroup, myofibroblasts, exhibits contractile features similar to smooth muscle cells. In colorectal cancer, FAP overexpression in fibroblasts has been associated with poor prognosis, including increased lymph node involvement, tumor recurrence, angiogenesis, and decreased overall survival. Learn more about the FAP inhibitors @ FAP Inhibitors Analysis Key Emerging FAP Inhibitors and Companies Key players in the FAP inhibitor market include AstraZeneca (AZD 2389), Sofie ([18F]FAPI-74; [68Ga]FAPI-46), BioXcel/OnkosXcel (BXCL701), Avacta Life Science (AVA6000), and several other companies. A radiopharmaceutical known as [18F] FAPI-74 combines FAPI-74, a quinoline-based compound that targets fibroblast activation protein (FAP), with the chelating agent NOTA (1,4,7-triazacyclononane-N,N',N'-triacetic acid), and is labeled with the positron-emitting isotope fluorine-18. It is designed for PET imaging of tumors and cancer-associated fibroblasts (CAFs) that express FAP. After administration, FAPI-74 binds to FAP-expressing tumor cells and CAFs. These bound cells can then be visualized via PET scans. FAP is a surface protein highly expressed in many cancers and in CAFs within the tumor microenvironment (TME). A Phase II clinical trial (NCT05641896) is underway to evaluate [18F] FAPI-74 PET imaging in patients with gastrointestinal cancers. This study is multicenter, single-arm, open-label, and non-randomized. In October 2023, SOFIE and GE HealthCare entered into a licensing agreement for the development and commercialization of [68Ga] FAPI-46 and [18F] FAPI-74. Under this deal, GE HealthCare acquired global rights to [68Ga] FAPI-46 and ex-U.S. rights to [18F] FAPI-74, while SOFIE retained U.S. rights for [18F] FAPI-74's clinical development and commercialization. AVA6000, a prodrug of the chemotherapy agent doxorubicin, functions by inhibiting an enzyme that promotes cancer cell growth. Unlike standard doxorubicin, AVA6000 remains inactive until it reaches tumor tissue, potentially reducing side effects. It is administered intravenously. On January 16, 2025, Avacta reported encouraging results from its Phase I trial of AVA6000. In patients with salivary gland cancer, five out of ten showed tumor shrinkage—ranging from partial to minor responses—with a disease control rate of 90%. The anticipated launch of these emerging therapies are poised to transform the FAP inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the FAP inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about FAP inhibitors clinical trials, visit @ FAP Inhibitors Treatment FAP Inhibitors Overview Fibroblast activation protein (FAP) is a type II transmembrane serine protease predominantly found on activated fibroblasts, especially within the tumor microenvironment and areas of tissue remodeling. It is largely absent in healthy adult tissues but becomes markedly upregulated in more than 90% of epithelial cancers, where it plays a key role in promoting tumor progression by remodeling the extracellular matrix, supporting angiogenesis, suppressing immune responses, and aiding tumor cell invasion. Elevated levels of FAP are also observed in various fibrotic and inflammatory conditions, including liver cirrhosis, pulmonary fibrosis, rheumatoid arthritis, and during wound healing, emphasizing its broader involvement in pathological tissue remodeling. Because of its disease-restricted expression and functional significance, FAP has gained traction as a target for diagnostic and therapeutic applications. Radiolabeled FAP inhibitors (FAPIs) have delivered strong results in PET imaging by offering high-contrast visualization of tumors and fibrotic tissues with minimal background interference. These promising outcomes have led to the development of FAP-targeted treatments such as radioligand therapies, antibody-drug conjugates, and CAR T-cell approaches designed to modulate the tumor stroma and boost anti-cancer activity. Nevertheless, challenges remain, particularly in achieving specificity over related proteases and managing potential side effects in fibrotic conditions. Current research efforts are focused on optimizing FAPI pharmacokinetics, enhancing therapeutic effectiveness, and evaluating synergistic strategies with immunotherapies. Notably, FAP-targeted imaging and treatment approaches are expanding beyond oncology into fields like cardiology, pulmonology, and autoimmune disease, underscoring its growing importance as a biomarker and therapeutic target with the potential to transform precision medicine for both cancer and fibrotic disorders. FAP Inhibitors Epidemiology Segmentation The FAP inhibitors market report proffers epidemiological analysis for the study period 2020–2040 in the 7MM, segmented into: Total Cases in Selected Indications for FAP Inhibitor Total Eligible Patient Pool in Selected Indications for FAP Inhibitor Total Treated Cases in Selected Indications for FAP Inhibitor FAP Inhibitors Report Metrics Details Study Period 2020–2040 FAP Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report NSCLC, Ovarian cancer, Pancreatic cancer, Metastatic colorectal cancer, Prostate cancer, Triple-negative breast cancer, Soft tissue sarcoma, and others Key FAP Inhibitors Companies SOFIE, BioXcel, OnkosXcel, AstraZeneca, Avacta, and others Key FAP Inhibitors [18F]FAPI-74, [68Ga]FAPI-46, BXCL701, AZD 2389, AVA6000, and others Scope of the FAP Inhibitors Market Report FAP Inhibitors Therapeutic Assessment: FAP Inhibitors' current marketed and emerging therapies FAP Inhibitors Market Dynamics: Conjoint Analysis of Emerging FAP Inhibitor Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, FAP Inhibitors Market Access and Reimbursement Discover more about FAP inhibitors in development @ FAP Inhibitors Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary of FAP Inhibitor 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. FAP Inhibitor Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2024 6.2. Market Share (%) Distribution by Therapies in 2040 6.3. Market Share (%) Distribution by Indications in 2024 6.4. Market Share (%) Distribution by Indications in 2040 7. FAP Inhibitor: Background and Overview 7.1. Introduction 7.2. Potential of FAP Inhibitor in Different Indications 7.3. Clinical Applications of FAP Inhibitor 8. FAP Target Patient Pool 8.1. Key Findings 8.2. Assumptions and Rationale: 7MM 8.3. Epidemiology Scenario in the 7MM 8.4. Total Cases in Selected Indications for FAP Inhibitor in the 7MM 8.5. Total Eligible Patient Pool for FAP Inhibitor in Selected Indications in the 7MM 8.6. Total Treated Cases in Selected Indications for FAP Inhibitor in the 7MM 9. Emerging Therapies 9.1. Key Competitors 9.2. [ F]FAPI-74: SOFIE 9.2.1. Product Description 9.2.2. Other developmental activities 9.2.3. Clinical development 9.2.4. Safety and efficacy 9.2.5. Analyst Views 9.3. AVA6000: Avacta List to be continued in the report 10. FAP Inhibitor: Seven Major Market Analysis 10.1. Key Findings 10.2. Market Outlook 10.3. Conjoint Analysis 10.4. Key Market Forecast Assumptions 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Size of FAP Inhibitor in the 7MM 10.6. Market Size of FAP Inhibitor by Indication in the 7MM 10.7. The United States 10.8. EU4 and the UK 10.9. Japan 11. Market Access and Reimbursement 12. SWOT Analysis 13. KOL Views 14. Unmet Needs 15. Bibliography 16. Report Methodology Related Reports Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Janssen Research and Development, Sanofi, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech and DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, among others. Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies, including AstraZeneca, Boehringer Ingelheim, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent, among others. Metastatic Colorectal Cancer Market Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies, including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, Innovative Cellular Therapeutics, among others. Pancreatic Cancer Market Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Yahoo
01-07-2025
- Business
- Yahoo
Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development
LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company's clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group's business development strategy. Dr. Liebowitz is a seasoned hematologist-oncologist and drug development leader with more than 30 years of experience across academia and industry and has contributed to the successful filing of more than 25 Investigational New Drug (IND) applications. He joins Avacta from Inovio Pharmaceuticals (Nasdaq: INO), where he served as Senior Vice President of early-stage clinical development, overseeing the clinical strategy for DNA-based vaccines and immunotherapies. Prior to that, he held senior roles at Xencor, Vaxart, and Amgen, with a consistent focus on oncology, immunotherapy, and translational science. At Vaxart, Dr. Liebowitz led the acquisition and execution of a significant BARDA contract as principal investigator, culminating in successful completion of the award. Earlier in his career, he held key R&D leadership roles at Amgen, where he directed oncology and vascular biology drug discovery at the company's Washington research site. Dr. Liebowitz began his academic career at the University of Chicago, where he served as Assistant Professor of Medicine and Virology and Director of the Bone Marrow Transplantation Program. He later became an associate investigator at the University of Pennsylvania's Abramson Cancer Institute, where he led immunotherapy and cellular therapy programs focused on cancer and chronic viral diseases, and was a recipient of a Bill & Melinda Gates Foundation grant. Dr. Liebowitz holds MD and PhD. degrees from the University of Chicago and BS and MS degrees from Emory University. Mr. Bogatyrenko is a Principal at Biopharma C&I, a biotechnology consulting firm that works with private and public companies in business development, corporate strategy, commercialization, launch readiness and R&D strategy. Previously, he held senior level positions in business development and commercial strategy, including leading multiple global commercial drug launches and numerous industry partnerships at Pfizer/Wyeth, Bayer Healthcare and Teva Specialty Pharmaceuticals. Christina Coughlin, MD, PhD, CEO of Avacta, commented: 'We are thrilled to welcome David and Yulii at this pivotal time for Avacta. David's deep expertise in oncology, coupled with a successful track record of advancing innovative therapies into the clinic, will be instrumental as we continue to execute on our clinical development strategy and progress our pre|CISION™ platform and pipeline of targeted cancer therapies. Yulii's deep experience across commercial strategy, global drug launches, and industry partnerships at leading pharma organizations will be invaluable as we advance our pipeline and corporate growth strategy.' 'We look forward to benefiting from their insights and strategic perspective as we remain focused on driving value for both patients and shareholders.' For further information from Avacta Group plc, please contact: Avacta Group plcMichael Vinegrad, Group Communications Director Peel Hunt (Nomad and Joint Broker)James Steel / Chris Golden Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark RogersZeus (Joint Broker)James Hornigold / George DuxberryDominic KingICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
LONDON and PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the appointments of David Bryant and Richard Hughes as Non-Executive Directors with immediate effect. David Bryant is a highly experienced international pharmaceutical executive with over 35 years in the industry. He has a strong track record in commercial leadership roles at GSK and Pfizer and was one of the original management team at Clinigen Group, from its 2012 IPO on AIM to its sale for $1.6bn in 2022. David is currently an Advisor to Healthcare Royalty (HCRx), a US-based healthcare focused private investment business. Richard Hughes has had a long and successful career in UK capital markets with over 30 years' corporate finance experience, including IPOs, equity capital raising and M&A for both public and private companies. He was previously a founder shareholder and a director of and a majority shareholder of Crawford Healthcare, a UK-based advanced wound care and dermatology company, which was acquired by Acelity in June 2018. He is a shareholder and director of numerous private companies operating across a range of sectors. Richard founded Zeus Capital, an independent financial services group, in 2003 and is a director of Zeus Group. Shaun Chilton, Non-Executive Chairman, commented: 'As Avacta completes its transformation into a dedicated pure play therapeutics company, focused on advancing our unique pre|CISION® platform for the benefit of patients, it needs seasoned and expert guidance. David and Richard have many years' experience and proven track records in pharmaceutical development and commercialization and capital markets respectively. Their collective expertise will significantly enhance the Board's capabilities as we focus on the strategic opportunities within our innovative pipeline to build long-term shareholder value.' commented: 'I am looking forward to working closely with the executive management team on Avacta's exciting technology and leveraging my commercial expertise. With the recent advances from the pre|CISION platform just published and the second program entering the clinic soon, the timing is ideal for me to join the Board.' added: 'I am delighted to be appointed as a Director. The business has a proprietary delivery platform in pre|CISION® that I believe will have a significant impact on the standard of care across a range of therapeutics, whilst limiting the harmful side effects that so many patients experience. I look forward to utilizing my experience in both fundraising and the scaling of businesses to assist the executive management team in delivering value for all shareholders.' For further information from Avacta Group plc, please contact: Avacta Group plcMichael Vinegrad, Group CommunicationsDirector Peel Hunt (Nomad and Joint Broker)James Steel / Chris Golden Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert avacta@ Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. Appendix 1: Further disclosures regarding David Bryant Avacta also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies. Full name: David John Bryant Age: 58 years Current directorships/partnerships: 60 Niton Street (Freehold) Limited 60 Niton Street RTM Ltd Mulberry Capital Management Ltd Previous directorships/partnerships held in the past 5 years: Clinigen Limited Nupharm Group Limited Pern Consumer Products Limited Protomed Limited Quantum Pharma 2014 Limited Quantum Pharmaceutical Limited Quantum Pharma Group Limited Quantum Pharma Holdings Limited Quantum Specials Trustee Limited Triley Bidco Limited Triley Midco Limited Triley Midco 2 Limited U L Medicines Limited Protomed Limited entered into a creditors' voluntary winding up process in February 2019. There were no secured or preferential creditors and as at April 2025 claims of c. £4.1m from unsecured creditors had been received which were in the process of being agreed and distributed. David Bryant does not hold any ordinary shares in Avacta. There are no other disclosures required in connection with the appointment David John Bryant under Schedule Two(g) of the Aim Rules for Companies. Appendix 2: Further disclosures regarding Richard Hughes Avacta also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies. Full name: Richard Ian Hughes Age: 57 years Current directorships/partnerships: Andratx Property Limited Bidco 2 Limited Bidco 3 Limited Bidco 4 Limited Dakarts Limited Elpis Holdings Limited Eternal Time Limited Irwell Investments Limited Medusa 19 Limited Medusa 19 Group Limited Medusa 19 Healthcare Limited Medusa Asset Management Limited Medusa Management Services Limited Medusa Partners LLP Oakdate Limited Palatine Private Equity LLP RHDL Limited Saturn Asset Management Limited Saturn Group Holdings Limited Saturn Pass Limited Saturn Passport Limited Stratford Place Property Investments Ltd Zeus Group Limited Previous directorships/partnerships held in the past 5 years: Newco (Huntingdon Street Nottingham) Limited The following disclosures are made in accordance with paragraphs (g) (v) and (vi) of Schedule Two of the AIM Rules: Richard Hughes was: appointed a director of Catalyst Securities Limited on 3 February 2006, a company incorporated in England. The company was placed into administration on 21 April 2011 and was subsequently dissolved on 14 November 2018, with approximately £9.3 million owing to creditors; appointed a director of Catalyst Securities No.2 Fund Limited on 3 February 2006, a company incorporated in England. The company was placed into administration on 13 September 2010 and was subsequently dissolved on 15 June 2013, with approximately £1.5 million owing to creditors; appointed a director of Catalyst Investments Limited on 18 January 2006, a company incorporated in England. The company entered a creditors' voluntary liquidation on 17 June 2011 and was subsequently dissolved on 23 April 2014, with approximately £9.5 million owing to creditors; appointed a director of Procurasell Holdings Limited on 30 October 2007, a company incorporated in England. The company entered a compulsory liquidation on 17 June 2009 and was subsequently dissolved on 24 August 2010; appointed a director of The Debt Advisor Group plc on 9 April 2003, a company incorporated in England. The company was placed into administration on 29 June 2007 and was subsequently dissolved on 10 April 2011, with approximately £2.3 million owing to unsecured creditors; appointed an LLP designated member of My SPA Liverpool LLP, a limited liability partnership incorporated in England, on 5 November 2008. The partnership entered a creditors' voluntary liquidation on 20 October 2009 and was subsequently dissolved on 25 May 2011, with an estimated £64,633 owing to unsecured creditors; and appointed an LLP designated member of My SPA Chesire LLP, a limited liability partnership incorporated in England, on 1 December 2008. The partnership entered a creditors' voluntary liquidation on 22 April 2010 and was subsequently dissolved on 16 July 2012, with approximately £31,000 owing to unsecured creditors. Richard Hughes does not hold any ordinary shares in Avacta. There are no other disclosures required in connection with the appointment Richard Ian Hughes under Schedule Two(g) of the Aim Rules for Companies.
Yahoo
28-05-2025
- Business
- Yahoo
Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors
LONDON and PHILADELPHIA, May 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announces the appointments of David Bryant and Richard Hughes as Non-Executive Directors with immediate effect. David Bryant is a highly experienced international pharmaceutical executive with over 35 years in the industry. He has a strong track record in commercial leadership roles at GSK and Pfizer and was one of the original management team at Clinigen Group, from its 2012 IPO on AIM to its sale for $1.6bn in 2022. David is currently an Advisor to Healthcare Royalty (HCRx), a US-based healthcare focused private investment business. Richard Hughes has had a long and successful career in UK capital markets with over 30 years' corporate finance experience, including IPOs, equity capital raising and M&A for both public and private companies. He was previously a founder shareholder and a director of and a majority shareholder of Crawford Healthcare, a UK-based advanced wound care and dermatology company, which was acquired by Acelity in June 2018. He is a shareholder and director of numerous private companies operating across a range of sectors. Richard founded Zeus Capital, an independent financial services group, in 2003 and is a director of Zeus Group. Shaun Chilton, Non-Executive Chairman, commented: 'As Avacta completes its transformation into a dedicated pure play therapeutics company, focused on advancing our unique pre|CISION® platform for the benefit of patients, it needs seasoned and expert guidance. David and Richard have many years' experience and proven track records in pharmaceutical development and commercialization and capital markets respectively. Their collective expertise will significantly enhance the Board's capabilities as we focus on the strategic opportunities within our innovative pipeline to build long-term shareholder value.' commented: 'I am looking forward to working closely with the executive management team on Avacta's exciting technology and leveraging my commercial expertise. With the recent advances from the pre|CISION platform just published and the second program entering the clinic soon, the timing is ideal for me to join the Board.' added: 'I am delighted to be appointed as a Director. The business has a proprietary delivery platform in pre|CISION® that I believe will have a significant impact on the standard of care across a range of therapeutics, whilst limiting the harmful side effects that so many patients experience. I look forward to utilizing my experience in both fundraising and the scaling of businesses to assist the executive management team in delivering value for all shareholders.' For further information from Avacta Group plc, please contact: Avacta Group plcMichael Vinegrad, Group CommunicationsDirector Peel Hunt (Nomad and Joint Broker)James Steel / Chris Golden Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert avacta@ Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients. Appendix 1: Further disclosures regarding David Bryant Avacta also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies. Full name: David John Bryant Age: 58 years Current directorships/partnerships: 60 Niton Street (Freehold) Limited 60 Niton Street RTM Ltd Mulberry Capital Management Ltd Previous directorships/partnerships held in the past 5 years: Clinigen Limited Nupharm Group Limited Pern Consumer Products Limited Protomed Limited Quantum Pharma 2014 Limited Quantum Pharmaceutical Limited Quantum Pharma Group Limited Quantum Pharma Holdings Limited Quantum Specials Trustee Limited Triley Bidco Limited Triley Midco Limited Triley Midco 2 Limited U L Medicines Limited Protomed Limited entered into a creditors' voluntary winding up process in February 2019. There were no secured or preferential creditors and as at April 2025 claims of c. £4.1m from unsecured creditors had been received which were in the process of being agreed and distributed. David Bryant does not hold any ordinary shares in Avacta. There are no other disclosures required in connection with the appointment David John Bryant under Schedule Two(g) of the Aim Rules for Companies. Appendix 2: Further disclosures regarding Richard Hughes Avacta also discloses the following information in accordance with Schedule 2(g) of the AIM Rules for Companies. Full name: Richard Ian Hughes Age: 57 years Current directorships/partnerships: Andratx Property Limited Bidco 2 Limited Bidco 3 Limited Bidco 4 Limited Dakarts Limited Elpis Holdings Limited Eternal Time Limited Irwell Investments Limited Medusa 19 Limited Medusa 19 Group Limited Medusa 19 Healthcare Limited Medusa Asset Management Limited Medusa Management Services Limited Medusa Partners LLP Oakdate Limited Palatine Private Equity LLP RHDL Limited Saturn Asset Management Limited Saturn Group Holdings Limited Saturn Pass Limited Saturn Passport Limited Stratford Place Property Investments Ltd Zeus Group Limited Previous directorships/partnerships held in the past 5 years: Newco (Huntingdon Street Nottingham) Limited The following disclosures are made in accordance with paragraphs (g) (v) and (vi) of Schedule Two of the AIM Rules: Richard Hughes was: appointed a director of Catalyst Securities Limited on 3 February 2006, a company incorporated in England. The company was placed into administration on 21 April 2011 and was subsequently dissolved on 14 November 2018, with approximately £9.3 million owing to creditors; appointed a director of Catalyst Securities No.2 Fund Limited on 3 February 2006, a company incorporated in England. The company was placed into administration on 13 September 2010 and was subsequently dissolved on 15 June 2013, with approximately £1.5 million owing to creditors; appointed a director of Catalyst Investments Limited on 18 January 2006, a company incorporated in England. The company entered a creditors' voluntary liquidation on 17 June 2011 and was subsequently dissolved on 23 April 2014, with approximately £9.5 million owing to creditors; appointed a director of Procurasell Holdings Limited on 30 October 2007, a company incorporated in England. The company entered a compulsory liquidation on 17 June 2009 and was subsequently dissolved on 24 August 2010; appointed a director of The Debt Advisor Group plc on 9 April 2003, a company incorporated in England. The company was placed into administration on 29 June 2007 and was subsequently dissolved on 10 April 2011, with approximately £2.3 million owing to unsecured creditors; appointed an LLP designated member of My SPA Liverpool LLP, a limited liability partnership incorporated in England, on 5 November 2008. The partnership entered a creditors' voluntary liquidation on 20 October 2009 and was subsequently dissolved on 25 May 2011, with an estimated £64,633 owing to unsecured creditors; and appointed an LLP designated member of My SPA Chesire LLP, a limited liability partnership incorporated in England, on 1 December 2008. The partnership entered a creditors' voluntary liquidation on 22 April 2010 and was subsequently dissolved on 16 July 2012, with approximately £31,000 owing to unsecured creditors. Richard Hughes does not hold any ordinary shares in Avacta. There are no other disclosures required in connection with the appointment Richard Ian Hughes under Schedule Two(g) of the Aim Rules for while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
28-04-2025
- Business
- Yahoo
Avacta Therapeutics Presents Preclinical and Translational Data from pre
FAP-EXd (AVA6103) demonstrates tumor growth inhibition and durable complete responses in multiple therapy-resistant preclinical models LONDON and PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced preclinical results from its second pre|CISION® candidate FAP-EXd (AVA6103) and new analyses around the potential of the pre|CISION® platform at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. The pre|CISION® programs are designed to target fibroblast activation protein-alpha (FAPα), the protease that forms the basis of the platform. FAP is consistently overexpressed across a broad range of solid tumors and enriched at the tumor-stroma interface, making it an ideal target for tumor-localized drug activation. Avacta's proprietary pre|CISION® chemistry leverages this tumor-specific biology to activate potent drugs selectively at the tumor site, enhancing efficacy while minimizing systemic toxicity. "The encouraging results we are showcasing at this year's AACR Annual Meeting highlight the versatility of our pre|CISION® platform,' said Michelle Morrow, CSO of Avacta Therapeutics. 'Our data presented today demonstrate that the platform can deliver potent payloads like exatecan with remarkable tumor selectivity and our novel sustained release mechanism. Together, these programs reinforce the broad potential of our pipeline to transform outcomes for patients and generate long-term value for shareholders.' AVA6103 (FAP-EXd) Preclinical Candidate Highlights (Abstract 3139, 28 April 2025) Avacta presented preclinical data from its second clinical candidate, AVA6103, a novel FAP-activated pre|CISION® PDC delivering the topoisomerase I inhibitor exatecan directly to the tumor-stroma interface. This mechanism minimizes systemic toxicity while ensuring precise delivery of the cytotoxic agent directly to the tumor with a sustained release mechanism that optimizes the pharmacokinetics of the released payload. Importantly, despite a very short half-life of 9 hours with conventional exatecan, FAP-EXd (AVA6103) is capable of delivering high tumor concentration vs. plasma with exposures of more than 60 hours projected with a single dose. Additionally, FAP-EXd's bystander effect enables exatecan to induce cytotoxicity in surrounding FAP-negative cancer cells, enhancing its therapeutic impact. The compound has demonstrated significant tumor growth inhibition and durable complete responses in multiple patient-derived xenograft models, including those that are resistant to topoisomerase I inhibition. These results reinforce the potential of FAP-EXd to deliver effective, targeted treatment with minimal off-target effects. The investigational new drug (IND) submission is anticipated in December 2025 and initiation of the first-in-human study in the first quarter of 2026. Abstract Number and Title: #3139: The novel PDC AVA6103 is a FAP-enabled pre|CISION® medicine which targets exatecan, a topoisomerase I inhibitor, to the tumor microenvironment following FAP cleavage· Session Category: Experimental and Molecular Therapeutics· Session Title: Therapeutic Approach to Attack the Tumor Microenvironment· Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT FAP Targeting Approach with pre|CISION® medicines (Abstract 2699, 28 April 2025) FAP is overexpressed across a wide range of solid tumors, with estimated frequency of over 90% of patients with evidence of FAP expression. This expression is spatially enriched at the tumor-stroma interface, demonstrating the effective nature of the pre|CISION® mechanism to deliver highly potent payloads directly to the tumor. Given the broad expression of FAP in human solid tumors and correlation of the protein and RNA levels of FAP, an AI-based approach to this target was employed with the Avacta strategic collaboration with Tempus. Avacta's work with Tempus has demonstrated several key aspects of the pre|CISION® platform, namely (1) FAP expression remains consistent across lines of therapy and in pre- and post-tumor samples, and (2) co-expression of genes associated with sensitivity to the payload and FAP identify the optimal patient populations for pre|CISION® medicines including FAP-EXd. These data reinforce the potential of Avacta's pre|CISION® platform to deliver potent therapies across multiple solid tumor indications with broad clinical utility. Abstract Number and Title: #2699: Investigating fibroblast activation protein alpha (FAPα) as a therapeutic target for delivery of pre|CISION® cancer medicines: Expression, spatial localization and functional insights· Session Category: Tumor Biology· Session Title: Targeting the Tumor Microenvironment: A Brave New World· Session Date and Time: Monday, April 28, 2025, 2:00 - 5:00 p.m. CT For further information from Avacta, please contact: Avacta Group plcMichael Vinegrad, Group CommunicationsDirector Peel Hunt (Nomad and Broker)James Steel / Chris Golden Panmure Liberum (Joint Broker)Emma Earl / Will Goode / Mark Rogers ICR HealthcareMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert avacta@ Investor ContactRenee Leck THRUST Strategic Communications renee@ Media ContactCarly ScadutoCarly Scaduto Consulting Carly@ About Avacta - Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates. About the pre|CISION® PlatformThe pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.
